CERo Therapeutics (CERO) Projected to Post Earnings on Wednesday

CERo Therapeutics (NASDAQ:CERO) is expected to be issuing its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.75) per share for the quarter.

CERo Therapeutics (NASDAQ:CERO) last released its quarterly earnings results on Wednesday, November 19th. The company reported ($9.10) EPS for the quarter.

CERo Therapeutics Price Performance

Shares of CERO stock opened at $0.04 on Friday. The stock’s fifty day moving average price is $0.06 and its 200 day moving average price is $2.45. The company has a market cap of $832,120.00, a price-to-earnings ratio of 0.00 and a beta of 0.27. CERo Therapeutics has a 1-year low of $0.04 and a 1-year high of $39.68.

Analyst Ratings Changes

CERO has been the topic of several recent analyst reports. D. Boral Capital reissued a “hold” rating on shares of CERo Therapeutics in a research note on Tuesday, November 18th. Maxim Group downgraded shares of CERo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CERo Therapeutics has an average rating of “Reduce” and a consensus price target of $45.00.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.